Document Detail


Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients.
MedLine Citation:
PMID:  16420395     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Available immunomodulatory and conventional steroid treatment regimens provide a limited symptomatic benefit for patients with progressive multiple sclerosis (MS). We performed an open trial on the short-term efficacy of repeated intrathecal application of the sustained release steroid triamcinolone acetonide (TCA) in 27 progressive MS patients. Six TCA administrations, performed every third day, reduced the Expanded Disability Status Scale (EDSS) score [initial: 5.4+/-1.3, 3-7.5 (mean+/-SD, range); end: 4.9+/-1.1; 2.5-6.5; P<0.001] and significantly increased the walking distance and speed in particular after the fourth TCA injection. Concomitantly serially determined cerebrospinal fluid (CSF) markers of cell injury, neuron-specific enolase, total tau-protein, S-100, and beta-amyloid did not significantly change within the interval of TCA treatment. No serious side effects appeared. We conclude that repeat intrathecal injection of 40 mg TCA provides a substantial benefit in progressive MS patients with predominant spinal symptoms and does not alter CSF markers of neuronal cell injury.
Authors:
V Hoffmann; W Kuhn; S Schimrigk; S Islamova; K Hellwig; C Lukas; N Brune; D Pöhlau; H Przuntek; T Müller
Related Documents :
22706615 - The role of periodic safety update reports in the safety management of biopharmaceuticals.
1569815 - Treatment of multibacillary leprosy with a regimen of 13 weeks duration.
22837555 - Intergroup conflict: ecological predictors of winning and consequences of defeat in a w...
22419265 - Fixed versus mobile weight-bearing prosthesis in total knee arthroplasty.
16504095 - Serum sickness-like reaction associated with cefazolin.
2965085 - Effectiveness of intraarterial plasminogen application in combination with percutaneous...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  European journal of neurology : the official journal of the European Federation of Neurological Societies     Volume:  13     ISSN:  1351-5101     ISO Abbreviation:  Eur. J. Neurol.     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2006-01-19     Completed Date:  2006-04-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9506311     Medline TA:  Eur J Neurol     Country:  England    
Other Details:
Languages:  eng     Pagination:  72-6     Citation Subset:  IM    
Affiliation:
Department of Neurology, Kamillus-Klinik, Asbach, and Department of Neurology, St Josef-Hospital, Ruhr-University, Bochum, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Analysis of Variance
Anti-Inflammatory Agents / administration & dosage*
Disability Evaluation
Disease Progression
Drug Administration Schedule
Female
Humans
Injections, Spinal / methods
Male
Middle Aged
Multiple Sclerosis / cerebrospinal fluid,  drug therapy*,  physiopathology
Phosphopyruvate Hydratase / cerebrospinal fluid
S100 Proteins / cerebrospinal fluid
Severity of Illness Index
Treatment Outcome
Triamcinolone Acetonide / administration & dosage*
Walking
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/S100 Proteins; 76-25-5/Triamcinolone Acetonide; EC 4.2.1.11/Phosphopyruvate Hydratase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consen...
Next Document:  A 9-year review of dystonia from a movement disorders clinic in Singapore.